top of page

Biopharma Pulse - 5/9-5/13 Week in Review

As we enter May, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on compared to XBI.

Table 1. BPIQ company weekly/monthly moves and YTD moves


Weekly Move (5/9-5/13)

YTD Move

All BPIQ Companies



CAR-T Companies



Gene Editing Companies






See the biggest moves from last week below:


Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!

*We never send you spam - unsubscribe anytime


Highlights for the week of 5/9-5/13

Biggest positive move

  • $BHVN +56.2% Pfizer to Acquire Biohaven Pharmaceuticals & Record reported revenues of $319 million

Biggest negative move

Additional big moves

  • $VERU +53.7% Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization

  • $BSGM +50.6% BioSig Technologies, Inc. Issues Shareholder Letter with Corporate Update on Recent Achievements

  • $TCRX +38.3% TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual Meeting

  • $ASRT +37.5% Assertio Reports First Quarter 2022 Financial Results

  • $LOGC +34.4% LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia.

  • $CGEM +23% Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl

  • $CRBU +22% Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy

  • $BBIO +14% bridgebio announces exclusive license agreement with bristol myers squibb to develop and commercialize bbp-398, a potentially best-in-class shp2 inhibitor, in oncology

  • $CMPS -11.3% COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults.

  • $ACIU -12.3% AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology.

  • $ZYNE -13% Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting

  • $CUE -15% Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers.

  • $OBSV -18.3% ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting.

  • $BLPH -28.3% Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results

  • $MREO -31.3% Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency- associated Emphysema.

  • $RMTI -32% Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial

  • $COGT -37.7% Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results

  • $EVAX -37.6% Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update

  • $CDTX -44.2% Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

  • $VLON -46.6% Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR

  • $TXMD -60% Reverse stock split effective May 6 at 5:01pm

Highlights for next week

  • To see next week's Big Movers HERE, subscribe. Learn more here.

  • Watch for quarterly reports from commercial companies

    • $ADMP

    • $ALBO

    • $CMRX

    • $IMPL

    • $KALA

    • $PLX

    • $RMTI

    • $TXMD

    • $PTN

  • $SYGGF SG016 additional SPRINTER data

  • $MBIO MB-107 interim Phase 1/2 data

  • $PASG PBGM01 additional Imagine-1 data

See our Big Movers post to learn about upcoming Movers throughout May and PDUFAs, after subscribing. Learn more here.



bottom of page